Background. Early antiretroviral therapy (ART) limits proviral reservoirs, a goal for human immunodeficiency virus type 1 (HIV-1) remission strategies. Whether this is an immediate or long-term effect of virologic suppression (VS) in perinatal infection is unknown.
The early establishment of latent human immunodeficiency virus type 1 (HIV-1) reservoirs, primarily in the long-lived, resting memory CD4 + T cells [1] [2] [3] [4] , precludes HIV-1 cure, with viremic rebound generally occurring within 2-4 weeks of stopping combination antiretroviral therapy (ART), and irrespective of prior ART duration [5] [6] [7] . Emerging data have shown that a small reservoir size achieved through early ART can promote sustained virologic control in the absence of ART (HIV-1 remission) in a small subset of infected individuals [8] [9] [10] [11] and is also predictive of delayed time to virologic rebound off ART [12, 13] .
Perinatal HIV-1 infection is distinct from adult infection with respect to widespread implementation of early treatment, as timing of infection can be established [14] . We and others have shown that early ART from infancy with sustained virologic suppression (VS) is associated with persistence of low concentrations of HIV-1-infected cells in the circulation as measured by HIV-1 DNA copies per million peripheral blood mononuclear cells (PBMCs) [15, 16] . Among early-treated children surviving to adolescence (median age, 12.6 years), 79% had circulating HIV-1 DNA concentrations of <10 copies per million PBMCs [15] . Similar reports of low HIV-1-infected cell concentrations following early ART were also reported in cross-sectional studies of Thai and South African children treated from early infancy, in support of the effects of early ART in perinatal infection to limit HIV-1 reservoirs [17, 18] . We performed a longitudinal study to examine the kinetics of HIV-1-infected cell concentrations during VS in perinatally HIV-1-infected (PHIV + ) children and youth who differed by their ages of virologic control after ART initiation.
MATERIALS AND METHODS

Study Population
We studied PHIV + children and youth enrolled in the Adolescent To be eligible for this analysis, participants must have confirmed VS after ART initiation and by 5 years of age, have maintained VS until the data freeze date of 1 July 2012, and have >1 PBMC specimen. Only samples with detectable HIV-1 DNA using the pol primer during at least 1 study visit were included in the analysis. ART was defined as a regimen including at least 3 antiretroviral drugs from at least 2 drug classes. Confirmed VS was defined as achieving 2 consecutive pVLs <400 copies/ mL after ART initiation; maintenance of VS was defined as maintaining pVL <400 copies/mL during the study, although single measures of pVL ≥400 copies/mL, in between pVL measurements <400 copies/mL, were allowed.
Quantification of HIV-1 DNA
Genomic DNA was isolated from PBMCs with the Qiagen Blood Midi kit (Qiagen, Valencia, California) and HIV-1 DNA quantified using a slight modification of a previously published droplet digital polymerase chain reaction method [19, 20] . The modification involved a change in the restriction enzyme used to digest the genomic DNA, which was with XbaI (New England BioLabs, Ipswich, Massachusetts) rather than BsaJI. The restriction digest was carried out at 37°C for 1 hour, followed by inactivation at 65°C for 20 minutes. HIV-1 DNA concentrations were determined from 4 replicate reactions containing 1000 ng total of genomic DNA with primers targeting HIV-1 pol (HBX2: 2536, 2662 [19, 20] ). For samples with low DNA concentration (<200 ng/µL), 8 replicate reactions containing 500 ng total of genomic DNA were run. The number of cells analyzed was determined by the concentration of the housekeeping gene RRP30. All assays were performed with equal numbers of negative controls containing genomic DNA from the MOLT-4 cell line and no template controls, along with 2 positive control reactions. The average limit of detection for the HIV-1 pol assay was 2.5 copies/million PBMCs (interquartile range, 1.5-2.7) for the 402 samples tested.
Statistical Analyses
Sociodemographic, HIV-1-specific characteristics (ART, CD4, pVL), and PBMC specimen characteristics were compared by the age at VS using either Fisher exact test or Wilcoxon ranksum test as appropriate. Locally weighted scatterplot smoothing (LOESS) plots were used to first obtain a graphical summary of the relationship between time since VS and HIV-1 DNA concentrations, for all study participants and then stratified by age at VS. Piecewise linear mixed-effects regression models were then fit to estimate HIV-1 DNA trajectories following VS for all study participants and by age at VS. To estimate trajectories by age at VS, age at VS as well as interaction terms between age at VS and the slope parameters were added to the model. A knot was placed at year 2 from VS, based on visual inspection of the LOESS plots and prior knowledge on changes in immune population at this age. Model-based mean PBMC-associated HIV-1 DNA load during VS and half-lives were calculated. Fisher permutation test was used to calculate P values for comparison of these estimates by age at VS group. In further analyses, HIV-1 DNA concentrations were normalized for the number of CD4 + T cells. This was done by dividing the original outcome of PBMC-associated HIV-1 DNA by the proportion of PBMCs that were CD4 + T cells.
RESULTS
Study Participants
Of the 451 HIV-1-infected children and adolescents enrolled in PHACS/AMP, 430 initiated ART by July 2012, 198 achieved confirmed VS by 5 years of age, and 73 maintained VS throughout follow-up ( Figure 1 ). Five participants had no or only a single PBMC sample available for testing. Seven participants were also excluded from analyses because HIV-1 DNA-positive cells were not detected in PBMC samples from all time points tested; failure to detect HIV-1 in these participants with known HIV-1 infection is likely due to primer mismatch as none of the samples tested detected HIV-1-positive cells. The remaining 61 study participants were stratified into 2 groups based on the age at VS: Group 1 (n = 13) achieved VS by age 1 and group 2 (n = 48) achieved VS after age 1 (between 1 through 5 years of age). The median duration of VS throughout the study period was 10.1 years. A median of 9 and 5.5 PBMC samples were available per study participant in groups 1 and 2, through a median follow-up of 11.9 and 9.5 years during VS, respectively. The median age at last study visit, defined as the date of the last specimen analyzed for HIV-1 DNA, was 12.6 years for both groups.
Participant Characteristics
Group 1 initiated ART at a median of 2.1 months of age, and achieved VS at a median of 5.9 months after starting ART, while group 2 initiated ART at 1.7 years and achieved VS within 10.2 months (Table 1) . At ART initiation, the pVL distribution was not significantly different between groups 1 and 2 (median, 5.7 log 10 copies/mL and 5.0 log 10 copies/mL, respectively; P = .08). Similarly, the distribution for CD4 percentage at ART initiation was not significantly different across groups (median, 31.5% and 28%, respectively; P = .19). Participants had an average of 3.7 pVL measures per year during VS follow-up. The majority had either zero (44%) or 1 (33%) pVL ≥400 copies/mL during VS follow-up; 9 participants had 2 pVL measures ≥400 copies/mL, 3 had 3 pVLs ≥400 copies/mL, and 2 had 5 pVLs ≥400 copies/mL during VS follow-up. The median pVL among the 57 observed measures ≥400 copies/mL (2.5% of 2298 total pVL measures) was 807 copies/mL. Table 2 ). Between years 2 and 14 from VS, the decrease in HIV-1 DNA concentrations was slower, at -0.05 (95% CI, -.06 to -.03) log 10 copies/million PBMCs per year. The estimated mean half-life of HIV-1 DNA from the time of VS was 16 years. With 10 years of VS, the estimated mean HIV-1 DNA concentration was 0.86 log lower than the concentration at the time of VS with a mean concentration of 1.39 (95% PI, .57-2.06) log 10 copies/million PBMCs (Table 3) . There was no difference in the estimated mean HIV-1 DNA concentrations at VS between groups 1 and 2 (2.24 and 2.18 log 10 copies/million PBMCs, respectively; P = .86) ( Figure 2 and Table   2 ). The decline in HIV-1 DNA concentrations during the first 2 years from VS was significantly faster in group 1 (-0.50 [95% CI, -.73 to -.27] log 10 copies/million PBMCs per year) compared with group 2 (-0.15 [95% CI, -.23 to -.07] log 10 copies/million PBMCs per year) (P = .005). This corresponded to a net decrease of 10-fold and 2-fold in HIV-1 DNA concentrations in the first 2 years of VS in groups 1 and 2, respectively. Between years 2 and 14 from VS, there was ongoing decay of HIV-1 DNA in both groups; however, the decay estimates were no longer significantly different between groups 1 and 2 (-0.03 [95% CI, -.06 to -.00] log 10 copies/million PBMCs per year and -0.05 [95% CI, -.07 to -.03] log 10 copies/million PBMCs per year, respectively) (P = .35). The estimated mean half-life of HIV-1 DNA from VS was shorter for group 1 compared with group 2 at 5.9 years and 18.8 years, respectively (P = .09). With 10 years of VS, the estimated mean HIV-1 DNA concentration reached a substantially lower level in group 1 at 0.99 (95% prediction interval, .51-1.54) log 10 copies/ million PBMCs compared with group 2 at 1.51 (95% prediction interval, .66-2.12) log 10 copies/million PBMCs (P < .001; Table 3 ).
Decay Dynamics of
Normalization for Changes in CD4 + T Cells
As CD4 reconstitution of immune cells following VS can have a dilutional effect on HIV-1-infected cell concentrations, we examined the effects of normalizing for the number of CD4 + T cells on the decay estimates. Essentially, the same decay kinetics of HIV-1 DNA was observed with normalization for CD4 + T-cell count ( Figure 3 and Table 4 ). At the time of VS, HIV-1 DNA concentration was estimated to be 2.63 log 10 copies/million CD4 cells in both groups and, as expected, was about 3-fold higher than in total PBMCs. Similar rates and differences in the decay of HIV-1 as a function of age at virologic control were found, with faster clearance in group 1 compared with group 2 in the first 2 years from VS (P = .005), and no difference between the 2 groups for 2-14 years of VS (P = .29).
DISCUSSION
This is the first study to report on the long-term decay dynamics of HIV-1-infected cells in perinatal infection with VS, as well as the difference in decay parameters by age at virologic control. These findings are pertinent for the timing of ART initiation in pediatric HIV-1 infection with relevance to achieving HIV-1 remission or posttreatment control of HIV-1 replication in absence of ART. We found that, in contrast to HIV-1-infected adults, sustained control of virus replication leads to substantial decreases in HIV-1-infected cells over childhood through adolescence, to reach the unprecedented low concentrations (mean of 1.39 log 10 copies per million PBMCs at 10 years after VS) desirable for viral remission strategies. This finding was consistent irrespective of age at VS. Importantly, however, earlier age at VS (by 1 year of age) was associated with larger decreases in the HIV-1-infected cell concentrations in the first 2 years following VS as compared to when virologic control occurred later (between 1 through 5 years of age; estimated mean decay rate of -0.50 log 10 copies/million PBMCs per year compared with -0.15 log 10 copies/million PBMCs per year, respectively). This difference in decay between the 2 groups could not be explained by differences in starting concentrations of HIV-1-infected cells, as there was no difference in the HIV-1-infected cell concentration at the time of VS, when first phase decay would have been completed. Similarly, differences in immune reconstitution between infants and young children or lymphoid expansion from somatic growth did not appear to contribute to the finding as adjustment for the percentages of CD4 + T cells did not alter the decay slopes. Together, these findings suggest qualitative differences in the types of reservoir cells generated as a function of age and duration of uncontrolled virus replication in perinatal infection, specifically the memory CD4 + T-cell reservoir with estimated half-lives ranging from 88 months to 277 months for transitional and T-memory stem cells, respectively [21] . Importantly, this difference is likely not due to preservation d Prophylaxis is defined as the first ART a given participant was on during life that also must have been both initiated and completed during the first 2 months of life.
of HIV-1-specific immune responses through earlier therapy, as HIV-specific immune responses are largely undetectable with early control of HIV-1 replication in infancy [22] [23] [24] . It is established that HIV-1-infected cells decrease by about 10-fold from the pre-ART concentrations during the first year of ART in both perinatal [20, 25, 26] and adult [27, 28] infection, reflective of clearance of shorter-lived, infected CD4 + T cells. In infected adults treated during chronic infection, the concentration of HIV-1-infected cells in the peripheral blood plateaus after 4 years on ART to a median of 2.84 log 10 copies Figure 2 . Decay of human immunodeficiency virus type 1 (HIV-1) DNA in peripheral blood mononuclear cells (PBMCs) following virologic suppression (VS) overall (11) and by age at VS (11) . Piecewise linear mixed-effects model of HIV-1 DNA decay in overall study population (solid black line) and in those who achieve VS by 1 year of age (solid blue line) and by 1 to 5 years of age (solid red line). Dashed lines represent fitted locally weighted scatterplot smoothing curve. Closed circles represent DNA levels below limit of detection. per million PBMCs, with no additional decay through a decade or more of ART [27] . Whether the steady state of persistence of HIV-1-infected cells occurs earlier than 4 years of ART is unknown, as this time point is influenced by the timing of sample collection in the study [27] . Likewise, in children initiating ART during chronic infection (median, 9 years of age), the concentration of HIV-1-infected cells stabilizes at 1.82 log 10 copies per million PBMCs after 4 years of ART [29] . This is consistent with the long-term stability of HIV-1-infected cells despite effective ART. However, ART initiation during acute infection may influence the long-term stability of HIV-1-infected cells through alterations in the types of memory CD4 + T-reservoir cells that are generated [11, 30] . A recent study comparing the size of the HIV-1 reservoir in adults treated during acute or chronic infection for a decade or more showed that ART during acute infection resulted in significantly smaller reservoir size compared with ART in chronic infection [8] . Our results showing faster HIV-1 decay and smaller reservoir size among children with VS by 1 year of age are consistent with these findings, implying that there are (11) and by age at VS (11) , normalized for CD4 cell count. Piecewise linear mixed-effects model of HIV-1 DNA decay in overall study population (black line) and in those who achieve VS by 1 year of age (blue line) and by 1 to 5 years of age (red line). HIV-1 proviral DNA decay by PBMCs (solid lines) and CD4 percentage (dashed lines). differences in the mechanisms of HIV-1 persistence when ART is started during the acute vs chronic stages of the infection. Several small cross-sectional studies in perinatally infected children have reported on the observation of fairly low concentrations of HIV-1-infected cells at 8-15 years of age in children on effective ART from early infancy [18, 31] . The extent to which this was a consequence of early restriction in HIV-1-infected cells is unknown. This is the first longitudinal study to examine HIV-1-infected cell decay over the time course of ART. Here, we show that the low-infected cell concentrations observed with early treatment is a longer-term effect of sustained control of HIV-1 replication from infancy with ART initiation at <3 months of age, rather than an immediate restriction in HIV-1-infected cell concentrations.
Importantly, despite the similarities in the initial concentrations of infected cells generated during acute HIV-1 infection in adult and perinatal infection [20, 28, 32] , and the ongoing decay of HIV-1-infected cells during a decade or more of early ART in infected adults [32] , the HIV-1-infected cell concentrations achieved with long-term ART were 15-fold lower in early-treated infants compared with early-treated adults. This difference highlights unique aspects of HIV-1-infected cell clearance and persistence in perinatal infection, especially with early and effective long-term treatment, for which processes such as slower development of long-term memory T-cell responses and homeostatic proliferation, along with lymphoid expansion and immune reconstitution from thymic output, may be responsible but require further investigation.
Our study was limited by the lack of availability of PBMCs before ART to directly estimate first-phase decay of infected cells with ART. However, we were able to previously demonstrate [20] that a high concentration of HIV-1-infected cells are present by 2 months of age, with similar decay in the first 2 years of ART, as observed in HIV-1-infected adults [28] . In addition, studies to explain the mechanisms of persistence of proviral genomes-specifically, distribution of proviral genomes by memory CD4 + T-cell subsets [33] and integration site analyses [34, 35] -were not feasible, but warrant further investigation. Last, given that >90% of HIV-1 DNA is replication defective [36] , the true size of the latent, replication-competent HIV-1 reservoir that reestablishes viremia when ART is stopped was not evaluable from the sample repository, although recent data suggest that these defective genomes can express viral proteins and may be targets for immune clearance [37] . However, HIV-1 DNA has recently been shown to serve as a predictor of posttreatment control and time to virologic rebound in the context of treatment during acute HIV-1 infection in adults [13, 38] .
In conclusion, the observation that HIV-1-infected cell concentrations decline to remarkably low levels in the peripheral circulation of perinatally infected preadolescent children and youth has important implications for novel treatment strategies aimed at HIV-1 remission and cure. With 10 years of effective virologic control, the proviral reservoir size was 3-fold lower in the early-suppressed group compared with the later-suppressed group. Understanding the unique properties of HIV-1 persistence in perinatal infection, as identified in this study, and its implications for virologic remission, is critical for advancing the field of HIV-1 remission and cure research toward improved ART-sparing approaches for HIV-1 control in this population.
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